

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Campbell Rogers, Elazer R. Edelman, and Daniel I. Simon

Serial No.:

08/823,999

Group Art Unit: 1644

Filed:

March 25, 1997

Examiner: Phillip Gambel

For:

*MODULATION OF VASCULAR HEALING BY INHIBITION OF
LEUKOCYTE ADHESION AND FUNCTION*

Assistant Commissioner
of Patents
Washington, D.C. 20231

AMENDMENT TO APPEAL BRIEF

Sir:

Further to the Appeal Brief filed on June 19, 2000, please amend the Appeal Brief as follows:

Page 19, change "Exhibit 6" to "Exhibit 5".

Two references referred to in the Brief, one for Exhibit 2 (Coats, et al.) and one for Exhibit 5 (ERASER), are enclosed with this Amendment,

Respectfully submitted,

Patrea L. Pabst
Reg. No. 31,284

Date: June 20, 2000
ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, GA 30309
404-873-8794 (Phone)
404-873-8795 (Fax)


U.S.S.N. 08/823,999
Filed March 25, 1997
Amendment to Appeal Brief



CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Amendment to Appeal Brief, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: June 20, 2000



Jean Hicks

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Campbell Rogers, Elazer R. Edelman, and Daniel I. Simon

Serial No.: 08/823,999

Group Art Unit: 1644

Filed: March 25, 1997

Examiner: Phillip Gambel

For: *MODULATION OF VASCULAR HEALING BY INHIBITION OF
LEUKOCYTE ADHESION AND FUNCTION*

Assistant Commissioner
of Patents
Washington, D.C. 20231

AMENDMENT

Sir:

Please amend the application as follows.

In the Claims

1. (twice amended) A method of inhibiting or reducing stenosis or restenosis of a blood vessel following injury to vascular tissue in a region of the blood vessel of a patient in need of treatment thereof, comprising:

administering systemically or at the site of the injury a pharmaceutically acceptable composition comprising a compound which specifically inhibits or reduces leukocyte [CD11d/CD18] integrin-mediated adhesion or function, wherein the integrin is selected from the group consisting of Mac-1 (CD11b/CD18), LFA-1 (CD11a/CD18), p150,95 (CD11c/CD18), and CD11d/CD18, wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with [CD11d/CD18] the integrins or their ligands and which block the interaction of the [CD11d/CD18] the integrins or their ligands with vascular